SCHEMBL6093804

SCHEMBL6093804

OCCOCCOCc1ccccc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.50
CHRM3 P20309 1/20 0.45
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
PARP10 Q53GL7 1/20 0.41
TAAR1 Q96RJ0 3/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP12 P39900 1/20 0.38
FFAR1 O14842 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
MAPT P10636 2/20 0.36
RAB9A P51151 2/20 0.36
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097310 1.00 IDO1 (0.50) IDO1CHRM3ALDH1A1KMT2AMEN1
SCHEMBL6097552 0.96 IDO1 (0.53) IDO1CHRM3ALDH1A1KMT2AMEN1
SCHEMBL18171748 0.88 IDO1 (0.61) IDO1CHRM3ALDH1A1KMT2APARP10
SCHEMBL6095871 0.85 IDO1 (0.50) IDO1CHRM3ALDH1A1KMT2APARP10
SCHEMBL31163835 0.82 IDO1 (0.47) IDO1CHRM3ALDH1A1KMT2APARP10
SCHEMBL10457912 0.81 IDO1 (0.53) IDO1CHRM3ALDH1A1KMT2APARP10
Alcohol SCHEMBL23234322 0.81 IDO1 (0.46) IDO1CHRM3ALDH1A1KMT2APARP10
SCHEMBL18171753 0.80 IDO1 (0.57) IDO1CHRM3ALDH1A1KMT2APARP10
SCHEMBL18171754 0.80 IDO1 (0.57) IDO1CHRM3ALDH1A1KMT2APARP10
SCHEMBL10701086 0.80 IDO1 (0.57) IDO1CHRM3ALDH1A1KMT2APARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US claimed
EP-1423356-A2 NOVEL AMINOBENZOEPHENONES Leo Pharma A/S (DK) 2004-06-02 EP claimed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US claimed
WO-2003018535-A2 NOVEL AMINOBENZOEPHENONES LEO PHARMA A/S (DK) 2003-03-06 WO claimed
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US disclosed
EP-1423356-A2 NOVEL AMINOBENZOEPHENONES Leo Pharma A/S (DK) 2004-06-02 EP disclosed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US disclosed
WO-2003018535-A2 NOVEL AMINOBENZOEPHENONES LEO PHARMA A/S (DK) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors IL1B, IL1A, TNF IDO1 323/4885CHRM3 4868/4885ALDH1A1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.